



A CASE REPORT OF MEDULLARY THYROID CARCINOMA: CYTOLOGICAL FEATURES AND THE ROLE OF PROCALCITONIN IN PREOPERATIVE DIAGNOSIS

Dr Sreechithra Kartha

Pathologist, Devi Clinical Laboratory, Kollam, Kerala. - Corresponding Author

Dr Ajith Rajan

Consultant Ent Surgeon, District Hospital, Kollam, Kerala.

Mr Umesh S.P

Chief Biochemist and Technical Manager, deviclinical, Laboratory, kollam, kerala

ABSTRACT

Medullary thyroid carcinoma (MTC) is an unusual neuroendocrine thyroid neoplasm. Cytological diagnosis is difficult, as other thyroid neoplasms can mimic MTC on fine needle aspiration cytology (FNAC). We present a case of MTC where the diagnosis was established by FNAC and semi-quantitative procalcitonin assay. FNAC showed a dispersed cell pattern, plasmacytoid morphology, cytoplasmic granules, and speckled chromatin. Calcitonin, the specific biomarker for MTC, has many drawbacks, which prompted us to measure serum procalcitonin. We are reporting this novel case because serum procalcitonin, a sepsis marker, is not routinely used as a marker for MTC.

KEYWORDS : Medullary thyroid carcinoma, plasmacytoid cells, calcitonin, procalcitonin

INTRODUCTION

Timely diagnosis of medullary thyroid carcinoma (MTC) is crucial, as early detection can improve prognosis. The main preoperative diagnostic tools are fine needle aspiration cytology (FNAC), ultrasonography, and serum calcitonin assay. Here, we report a case of MTC that was diagnosed by FNAC, aided by semi-quantitative procalcitonin (PCT) assay.

CASE REPORT

A 21-year-old woman presented with swelling in the front of the neck. Physical examination showed a solitary nodule measuring 2 × 2 cm in the left lobe of the thyroid. There were no palpable cervical lymph nodes. Her maternal grandmother died of thyroid neoplasm 30 years previously, but no reports were available. Thyroid function test results were normal. Ultrasonography showed an iso-hypoechoic lesion with increased vascularity in the left lobe of the thyroid. FNAC was performed using a non-aspiration technique with a 23-gauge needle. Smears were prepared and stained using the Papanicolaou method.

Microscopy revealed cellular smears [Figure 1]. The cells were predominantly plasmacytoid [Figure 2] and dispersed with no clustering or syncytial pattern of arrangement. The individual cells had moderate to abundant cytoplasm and eccentric nuclei with speckled chromatin [Figure 3]. Prominent nucleoli were visible in some cells. Binucleate cells and some spindle cells were noted.

These cytological features raised the suspicion of MTC. Instead of serum calcitonin, which requires stringent conditions for sample storage and transport, we performed a semi-quantitative procalcitonin assay by an immunochromatographic method. In this test, the color intensity of the band is directly proportional to the PCT concentration of the sample, which is interpreted with the help of reference card. A red band was observed, indicating PCT ≥ 2 µg/L. This suggested a diagnosis of MTC, and the patient was referred to a higher center for treatment. The serum calcitonin assay performed there showed markedly elevated calcitonin levels. Histopathology confirmed MTC.

DISCUSSION

Even though MTC has definite preoperative diagnostic tools,^[1] the detection rate is lower than other thyroid malignancies. Cytological typing of MTC can be achieved with a high degree of accuracy, but it can also be mistyped, as various types of thyroid malignancies have similar morphologic features.^[2]

Generally, MTC aspirates are cellular with a dispersed cell pattern,^[3] syncytial patterns are common, and papillary and follicular

patterns are usually not present. The cells are very pleomorphic, being small round to cuboidal, plasmacytoid, triangular polyhedral, and spindle shaped.^{[3],[4]} The cytoplasm demonstrates coarse azurophilic granules with Romanowsky stain.^[3] The nuclei are usually eccentric, having punctate chromatin and inconspicuous nucleoli. Binucleation and multinucleation are also common features. Occasionally, cytoplasmic inclusions are present, and amyloid can be demonstrated in the background.^{[3],[4]}

The differential diagnoses in our case included Hurthle cell neoplasms, hyalinizing trabecular tumor, oncocytic variant of papillary thyroid carcinoma, and malignant melanoma. When an aspirate shows a dispersed monomorphic pattern of plasmacytoid cells with no other features definitively pointing to any specific thyroid malignancy, it is prudent to perform a biochemical marker assay to exclude MTC.^[4]

Calcitonin, the specific biochemical marker for MTC, is produced by cleavage and posttranscriptional modification of procalcitonin.^[5] The bioactive form of the hormone is a 32-amino acid monomeric peptide with a disulfide bridge at the amino terminus. Several limitations compromise the utility of calcitonin in preoperative diagnosis, including the following:^[7]


- 1) The serum levels of calcitonin may vary markedly during the day, reflecting the pulsatile secretion of the hormone.
- 2) Calcitonin is rapidly degraded by serum proteases at room temperature. A 50% decrease in serum calcitonin levels has been observed in samples that are not processed properly.

Therefore, in less well-equipped laboratory spaces, it is not easy to perform a reliable calcitonin assay. This can lead to a delay in diagnosis. The PCT assay does not have these issues.^{[7],[8],[9]} Serum PCT levels are very low in healthy individuals (< 0.05 ng/mL), and PCT levels > 0.25 ng/mL have been observed in patients with MTC.^[9] PCT has an independent *in vitro* half-life of 20-24 hours, and it does not need to be kept on ice or frozen. Evidence also suggests that some MTCs preferentially secrete PCT, the monitoring of which is becoming a method of choice for tumors failing to secrete calcitonin adequately.^[10]


CONCLUSION

The characteristic cytologic features of MTC are a dispersed cell pattern with varying cell morphology (plasmacytoid/spindle/small cell), eccentric nuclear position, azurophilic granules in the cytoplasm, and speckled chromatin. Since these overlap with the features of other thyroid neoplasms, it is advisable to assay

biochemical markers. A semi-quantitative PCT assay can be helpful in situations where the calcitonin assay is not readily available.



[Figure 1] FNAC smears showing increased cellularity (Pap stain, 10X)



[Figure 2] FNAC smear showing dispersed cell pattern (Pap stain 40X)




Figure 3] FNAC smears showing plasmacytoid cells with eccentric nuclei and speckled chromatin. (Pap stain 100X)

REFERENCES

- 1) Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009;19:1167-214.
- 2) Shah SS, Faquin WC, Izquierdo R, Khurana KK. FNA of misclassified primary malignant neoplasms of the thyroid: Impact on clinical management. *Cytojournal* 2009;6:1.
- 3) Orell SR, Sterrett GF, Whitaker D. *Fine Needle Aspiration Cytology*; 4th ed. (Elsevier, New Delhi) 2005:125-64.
- 4) Kini SR. *Thyroid cytopathology An Atlas And Text*. (Lippincott Williams and Wilkins, Philadelphia) 2008:277-85.
- 5) Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. *Best Pract Res Clin Endocrinol Metab* 2008;22:941-53.
- 6) Karges D, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, et al. German Society for Endocrinology (DGE)-Thyroid section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goitre: German evidence-based consensus recommendation. *Exp Clin Endocrinol Diab* 2005;112:52-8.
- 7) Algeciras-Schimmich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK. Procalcitonin: A Marker for the Diagnosis and Follow-Up of Patients with Medullary Thyroid Carcinoma. *J Clin Endocrinol Metab* 2009;94:861-8.
- 8) Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuss M, Görge R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. *Clin Chem* 2011;57:467-74.
- 9) Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. *J Clin Endocrinol Metab* 2014;99:2986-94.
- 10) Bugalho MJ, Madureira D, Domingues R, Pereira T, Cortez L. Medullary thyroid carcinoma preferentially secreting procalcitonin. *Thyroid* 2014;24:1190-1.